MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.
Welcome
Multiple sclerosis, or MS, is an autoimmune disease that affects the brain and spinal cord. While the exact cause is unknown, the leading theory suggests an unknown substance triggers the immune system, causing it to attack myelin, the fatty covering over the nerves.
As inflammation and myelin breakdown occur, scarring or sclerosis develops, interrupting nerve signals throughout the nervous system. The result is problems with vision, movement, thinking, muscle strength, and eventually disability.
Anyone can get MS, but it is two to three times more common in women between the ages of 20 and 50. MS also affects white people more often and is most common in areas farther from the equator, though not everyone in these locations has the same risk.
Some areas, like Canada and the Middle East, have a high or increasing prevalence of multiple sclerosis. In Canada, 250 per 100,000 people have multiple sclerosis, while Israel sees 141 cases per 100,000.
Multiple sclerosis is unpredictable and affects people differently. Relapsing-remitting MS causes acute symptoms with periods of remission, while other types may progress rapidly or slowly. Early MS might also be confused with other conditions. Symptoms include:
Treatment for MS is divided into two groups: treatment for relapse or flare-ups and long-term disease-modifying therapies. The type of treatment will depend on the severity of the MS and the general health and age.
The goal of DMT is to slow down the progression of multiple sclerosis. These medications usually target the immune system and include:
Monoclonal antibodies, interferons, and glatiramer acetate are often the first treatments used. Studies suggest monoclonal antibodies are highly effective against MS, with a 49 to 69 percent reduction in annual relapse rate, depending on the drug. Some immunomodulators and Nrf2 activators are also moderately effective and lower the annual relapse rate by 48 to 60 percent.
The goal of acute relapse or flare-up treatment is to dampen or interrupt immune activity, which helps manage symptoms and slow attacks. The most common treatment is high-dose methylprednisone pulse therapy, which can improve symptoms within days. For steroid-refractory cases, plasmapheresis is effective, reducing symptoms by 66 to 86 percent.
All MS medications have side effects, most of which are flu-like symptoms or injection site reactions, though other, more severe side effects exist. Common adverse effects of DMT vary by the drug but can include:
Patients can manage minor side effects with over-the-counter medicines, but liver enzymes and lymphopenia should be monitored with blood work. Some drugs have less common but serious side effects with long-term use. For example, a known risk of monoclonal antibodies and immunomodulators is a rare, opportunistic brain infection from the John Cunningham virus. Some drugs may also have cancer and hepatotoxicity risks.
After a diagnosis, your patients will have questions. They may want to know the impact MS will have on their life, their prognosis, the treatments available, and the possible side effects. Patients may also seek your opinion, guidance, and even reassurance on the best treatment for their case.
An MS diagnosis can cause significant fear and anxiety for the patient and their family. The best approach to any questions is to offer a compassionate discussion about the disease and treatments available while giving the patient accurate facts. Discuss their options based on the current guidelines and the associated risks, and share your insight on the best course of action.
However, patient emotional needs may also extend beyond the limited time available in a clinical setting. Access to therapy, clinical nurse support, and support groups can help patients come to terms with their new diagnosis. Studies suggest patient support groups can help new MS patients gain positive perceptions.
Understanding multiple sclerosis and the emerging data on treatments and trends is critical to patient care. Explore a variety of multiple sclerosis courses by joining the MDBriefCase community for free to stay current on clinical guidelines.
199 Bay Street #4000, Toronto,
ON M5L 1A9
In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Lab website (the “Website”), you (“You”) expressly agree to the following:
Review: MDBriefCase is pleased to consider the publication of Your Work on the Website. The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.
Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered. If posted, You will be identified as the author of the Work, or co-author if applicable.
Grant of Rights: As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats: (1) the exclusive right of first publication worldwide; (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications. The grant of rights survives termination or expiration of this Agreement.
Warranty: You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work. This warranty survives termination or expiration of this Agreement.
Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.
The Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished. When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.
Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.
Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words.
MDBriefCase reserves the right to accept or reject any submission and the right to condition acceptance upon revision of material to conform to its criteria.
There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal websites, corporate websites and social media platforms.
Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement.
